View More Recent Stories
-
Bruker (BRKR) PT Lowered to $70 at TD Cowen
-
Bruker (BRKR) PT Lowered to $70 at Stifel
-
Bruker (BRKR) PT Lowered to $80 at JPMorgan
-
Bruker (BRKR) Reports In-Line Q3 EPS ; Offers Guidance
-
Bruker (BRKR): European Unified Patent Court Rules in Favor of Bruker and NanoString, Invalidating Patent Asserted By 10x Genomics against NanoString’s CosMx SMI Products
-
Bruker (BRKR) Presents Major Innovations Across the Spectrum of Proteomics Research Applications at the HUPO World Congress
-
Barclays Assumes Bruker (BRKR) at Overweight
-
Bruker (BRKR) Forms New Bruker Spatial Biology Division
-
Bruker (BRKR) Acquires Dynamic Biosensors
-
Wolfe Research Downgrades Bruker (BRKR) to Peerperform
-
Citi Reiterates Buy Rating on Bruker (BRKR)
-
TD Cowen Reiterates Hold Rating on Bruker (BRKR)
-
Bruker (BRKR) PT Lowered to $72 at TD Cowen
-
Bruker (BRKR) Announces Strategic Minority Investment in NovAliX
-
Bruker (BRKR) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY24 Guidance
-
10 policies if Trump wins and stock implications: Jefferies
-
Bruker (BRKR) Announces that Injunction Impacting NanoString’s CosMx Spatial Molecular Imager Products in Germany Has Been Suspended

